Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia

Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia

US Patent 11053318 · Granted Jul 6, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Antibody constructs for CDH19 and CD32025
Antibody constructs for CDH19 and CD32025
Antibody constructs for DLL3 and CD32025
PSMA and CD3 bispecific T cell engaging antibody constructs2025
Antibody constructs for DLL3 and CD32025
Antibody constructs for CDH19 and CD32025
Cross-species-specific PSMAxCD3 bispecific single chain antibody2025
Cross-species-specific PSMAxCD3 bispecific single chain antibody2025
Binding molecules for BCMA and CD32025
Binding molecules for BCMA and CD32025
Binding molecules for BCMA and CD32025
Binding molecules for BCMA and CD32025